期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Medical Research Frontier. 2022; 6: (3) ; 53-55 ; DOI: 10.12208/j.imrf.20220105.

Study on the effect of tumor marker test in the diagnosis of gastric cancer
肿瘤标志物检验在胃癌诊断中的效果研究

作者: 陈小冬 *, 漆波, 陶青兰, 赵洪民

遂宁市第三人民医院 四川遂宁

*通讯作者: 陈小冬,单位:遂宁市第三人民医院 四川遂宁;

发布时间: 2022-08-29 总浏览量: 408

摘要

目的 探究肿瘤标志物检验在胃癌诊断中的效果。方法 选择本院2019.03-2022.03期间收诊的胃癌病人作为研究对象,共计70名设为实验组。同期选出至我院体检科进行健康体检者作为对比对象,共计70名设为常规组。分别对两组对象开展肿瘤标志物检测,记录和对比肿瘤标志物含量检验结果。将实验组纳入胃癌病人以病情分化不同,分出低分化型组(31名)、中高分化型组(39名),记录和对比肿瘤标志物阳性检出率。结果 相较常规组,实验组对象肿瘤标志物检出含量更高,P<0.05。实验组中相较低分化型组,中高分化型组肿瘤标志物阳性检出率更高,P<0.05。结论 胃癌诊断中检验肿瘤标志物水平应用价值高,可提高胃癌诊断率,建议普及应用。

关键词: 胃癌;肿瘤标志物;检验;诊断

Abstract

Objective To explore the effect of tumor marker test in the diagnosis of gastric cancer.
Methods a total of 70 patients with gastric cancer admitted in our hospital from March 2021 to March 2022 were selected as the subjects of the study. In the same period, 70 persons who went to the physical examination department of our hospital for physical examination were selected as the control group. The two groups were tested for tumor markers, and the test results of tumor marker content were recorded and compared. The patients in the experimental group were divided into low differentiation group (31 cases) and medium and high differentiation group (39 cases) according to their different conditions. The positive detection rates of tumor markers were recorded and compared.
Results compared with the routine group, the content of tumor markers in the experimental group was higher (P<0.05). The positive rate of tumor markers in the middle and high differentiation group was higher than that in the low differentiation group (P<0.05).
Conclusion   the detection of tumor markers in the diagnosis of gastric cancer has high application value, which can improve the diagnosis rate of gastric cancer.

Key words: Gastric cancer; Tumor markers; Inspection; Diagnosis

参考文献 References

[1]李先裴. 血清肿瘤标志物CEA、CA199、NSE和CYFR211联合检验对老年胃癌的诊断价值[J]. 疾病监测与控制,2021,15(06):435-437.

[2]王有法. 肿瘤标志物CA724、CEA、CA242、CA199联合检测检验在胃癌临床诊断中的价值分析[J]. 中国社区医师,2021,37(26):130-131.

[3]闫慧霞,陈国庆等. 肿瘤标志物癌胚抗原、糖类抗原、神经元特异性烯醇化酶和细胞角质蛋白联合检验对老年胃癌的诊断价值[J]. 内蒙古医学杂志,2020,52(10):1226-1227.

[4]朱付英,李瑾. 肿瘤标志物检验在胃癌诊断中的临床价值分析[J]. 中国继续医学教育,2020,12(11):82-83.

[5]周世繁,孙宏新. mEOX与FOLFIRI方案化疗对晚期胃癌患者疗效、血清肿瘤标记物及预后的影响比较[J]. 山东医药, 2018 ,58 (38):46-48

[6]韩莹波,崔丹,董红梅,等. 血清MG-Ag、CEA、CA19-9和CA72-4联合检测对胃癌的诊断价值[J].2019,(3).

[7]周燕,祁春茹,王瑞雪,等. 肿瘤标志物联检与肺癌诊断及中医辨证分型关系研究[J]. 光明中医,2018,33(20):2963-2965.

[8]晋飞. 胃蛋白酶原联合肿瘤标志物检测预测胃癌发生的价值评估[J]. 世界最新医学信息文摘(连续型电子期刊),2020,20(57):202-203.

[9]周绍坚,黄彩霞,昌裕淋,等. 分析肿瘤标志物联检在胃癌早期诊断的临床应用[J]. 世界最新医学信息文摘(连续型电子期刊),2019,19(47):164,166.

[10]董晓微,崔学强,张俊华,等. 血清肿瘤标志物CA19-9、CA72-4、CEA、PGⅠ联合检测对胃癌的诊断及预后价值分析[J].2018,(17).


引用本文

陈小冬, 漆波, 陶青兰, 赵洪民, 肿瘤标志物检验在胃癌诊断中的效果研究[J]. 国际医药研究前沿, 2022; 6: (3) : 53-55.